{{$DoctorName}} @if(isset(session()->get('doctor')['vCentralCode'])) {{session()->get('doctor')['vCentralCode']}} @endif
@if(isset(session()->get('doctor')['vCentralCode']))
Logout
@endif

{{$ActivityTypeName}}

{{$ActivityName}}

@csrf
@if(isset(session()->get('doctor')['vCentralCode']))
Back
@else
@endif
Lipodox Survey 2
    {{--1--}}
  1. For treatment of platinum sensitive relapsed ovarian cancer patients: *
    2. If your patients had grade 1-2 neurotoxicity in 1line, will you consider re-challenging with Paclitaxel

    If your patients had grade 3-4 neurotoxicity in 1st line, will you consider re-challenging with Paclitaxel

    {{--2--}}
  2. If your patient has diabetes, will you consider re-challenging with paclitaxel + carboplatin in following type of diabetic condition: *
    3. Uncontrolled diabetes

    Controlled diabetes

    {{--3--}}
  3. Do you see scope of Gemcitabine + Platinum & PLD + Platinum in platinum sensitive ovarian cancer? *

    4. {{--4--}}
  4. Do you consider BRCA testing for all ovarian cancer patients? *

    5. {{--5--}}
  5. In your clinical practice, what % of ovarian cancer patients have following mutational status? *
    6. BRCA mutated
    %
    HRD Positive
    %
    BRCA & HRD negative
    %
    {{--6--}}
  6. After treatment with Paclitaxel + platinum agent in 1L, what percentage of your ovarian cancer patients achieve following responses? *
    7. CR
    %
    PR
    %
    SD
    %
    {{--7--}}
  7. What percentage of your ovarian cancer patients receive PARP inhibitors in following treatment lines? *
    8. 1st Line
    %
    2nd Line
    %
    Beyond 2nd Line
    %
    {{--8--}}
    {{--
  8. In your clinical practice, Which PARPi you prefer as 1L maintenance therapy for BRCA +ve patients ovarian cancer patient (if cost is a concern): *--}}
  9. In your clinical practice, Which PARPi you prefer as 1L maintenance therapy for BRCA +ve patients ovarian cancer patient (if cost is a concern) : *

    10. {{--9--}}
    {{--
  10. In your clinical practice, Which PARPi you prefer as 1L maintenance therapy for BRCA +ve patients ovarian cancer patient (if cost is not a concern) *
    11. --}}
  11. In your clinical practice, Which PARPi you prefer as 1L maintenance therapy for BRCA +ve patients ovarian cancer patient (if cost is not a concern) : *

    12. {{--10--}}
  12. In your clinical practice, Which PARPi you prefer as 1L maintenance therapy for BRCA-ve / HRD+ve patients ovarian cancer patient (if cost is a concern) : *

    13. {{--11--}}
  13. In your clinical practice, Which PARPi you prefer as 1L maintenance therapy for BRCA-ve / HRD +ve patients ovarian cancer patient (if cost is not a concern) *

    14. {{--12--}}
  14. In your clinical practice, Which PARPi you prefer as 1L maintenance therapy for ovarian cancer patients with following mutational status: *
    15. Mutation status Cost is not concern Cost is concern
    BRCA –VE, HRD -VE

    {{--13--}}
  15. Currently, around 25-30% of ovarian cancer patients relapse in < 6 months. Role of PARP inhibitors have shifted from 2L maintenance to 1L maintenance treatment. PFS benefit offered by PARP inhibitors is more than 2 years… Ex. Olaparib 1L maintenance PFS 56 months Keeping this fact in mind, as per your opinion, will the pool of platinum resistant ovarian cancer patients would shrink? *

    16. {{--

    --}} {{-- --}} {{-- --}} {{--

    --}}
    {{--14--}}
  16. What is the average PFS that you observe in: *
    17. Newly diagnosed ovarian cancer
    months
    1st relapse platinum sensitive ovarian cancer
    months
    2nd relapse platinum sensitive ovarian cancer
    months
    3rd relapse & beyond
    months
    {{--15--}}
  17. In your clinical practice, what % of relapsed ovarian cancer patients suffer from carboplatin induced hypersensitivity reactions on rechallenge? *
    18. %